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1. INTRODUCTION {#jcmm14591-sec-0001}
===============

Rheumatoid arthritis (RA) is a chronic disease mediated by autoimmune responses with manifestations like systemic inflammation.[1](#jcmm14591-bib-0001){ref-type="ref"}, [2](#jcmm14591-bib-0002){ref-type="ref"} Various studies have shown that genetic and environmental risk factors together contribute to the development of RA.[3](#jcmm14591-bib-0003){ref-type="ref"}, [4](#jcmm14591-bib-0004){ref-type="ref"}, [5](#jcmm14591-bib-0005){ref-type="ref"}, [6](#jcmm14591-bib-0006){ref-type="ref"} An increasing number of studies are identifying a correlation between the cytokine networks and the RA pathogenesis.[7](#jcmm14591-bib-0007){ref-type="ref"}, [8](#jcmm14591-bib-0008){ref-type="ref"} At present, tremendous achievement has been seen in developing effective treatment of RA, in which suppressing the inflammatory responses is the most effect method.[5](#jcmm14591-bib-0005){ref-type="ref"}, [9](#jcmm14591-bib-0009){ref-type="ref"}, [10](#jcmm14591-bib-0010){ref-type="ref"} However, further studies are necessary to discover the mechanism in inflammatory responses of RA.[11](#jcmm14591-bib-0011){ref-type="ref"} Long non‐coding RNAs (lncRNAs), transcripts in length longer than 200 nc, show the crucial role in inflammation.[12](#jcmm14591-bib-0012){ref-type="ref"}, [13](#jcmm14591-bib-0013){ref-type="ref"} For example, in the collagen, antibody induced arthritis mouse model of RA, shikonin can suppress the inflammation by targeting specific lncRNAs,[14](#jcmm14591-bib-0014){ref-type="ref"} and in presence of quercetin, the apoptosis of fibroblast‐like synoviocytes (FLS) in RA was also blocked, in which the involvement of lncRNA MALAT1 plays a critical role.[15](#jcmm14591-bib-0015){ref-type="ref"}, [16](#jcmm14591-bib-0016){ref-type="ref"}, [17](#jcmm14591-bib-0017){ref-type="ref"}, [18](#jcmm14591-bib-0018){ref-type="ref"}, [19](#jcmm14591-bib-0019){ref-type="ref"}, [20](#jcmm14591-bib-0020){ref-type="ref"}, [21](#jcmm14591-bib-0021){ref-type="ref"}, [22](#jcmm14591-bib-0022){ref-type="ref"} In this study, we attempted to discover how MEG3 affects the proliferation and inflammation of LPS‐treated chondrocytes in RA.

2. MATERIAL AND METHODS {#jcmm14591-sec-0002}
=======================

2.1. Cell culture {#jcmm14591-sec-0003}
-----------------

Chondrocytes were separated from cartilaginous tissues of male SD rats (200‐280 g). (detailed in the Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}).

2.2. Lentiviral infection {#jcmm14591-sec-0004}
-------------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.3. qRT‐PCR {#jcmm14591-sec-0005}
------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.4. CCK‐8 assay and crystal violet staining {#jcmm14591-sec-0006}
--------------------------------------------

CCK‐8 assay and crystal violet staining were performed according to manufactures' instruction (detailed in the Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}).

2.5. Western blot analysis {#jcmm14591-sec-0007}
--------------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.6. Transfection of mimics {#jcmm14591-sec-0008}
---------------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.7. Dual‐luciferase assay {#jcmm14591-sec-0009}
--------------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.8. Immunohistochemistry {#jcmm14591-sec-0010}
-------------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.9. Flow cytometry {#jcmm14591-sec-0011}
-------------------

See Appendix [S1](#jcmm14591-sup-0001){ref-type="supplementary-material"}.

2.10. Statistics {#jcmm14591-sec-0012}
----------------

GraphPad Prism V was utilized for statistical analysis. The data were expressed as the mean ± standard error of the mean (SEM). All experiments were conducted a minimum of three times. A *P* value of \<.05 suggested statistical significance.

3. RESULTS {#jcmm14591-sec-0013}
==========

3.1. Upregulation of MEG3 in RA {#jcmm14591-sec-0014}
-------------------------------

To identify the divergence of MEG3 expression in the synovial tissues of healthy and RA subjects, we examined MEG3 expression in these subjects and found significant upregulation of MEG3 expression in the synovial tissue of RA patients (Figure [1](#jcmm14591-fig-0001){ref-type="fig"}A). Moreover, MEG3 expression was up‐regulated in the FLS obtained from the RA synovial tissue (Figure [1](#jcmm14591-fig-0001){ref-type="fig"}B). Thus, upregulation of MEG3 expression is conducive to RA.

![MEG3 affected the proliferative activity and inflammatory responses of LPS‐treated chondrocytes. A, qRT‐PCR results of MEG3 expression in synovial tissues of healthy subjects and RA patients. B, qRT‐PCR results of MEG3 expression in FLS of healthy individuals and RA patients. C, mRNA expression of MEG3 by RT‐PCR. D, mRNA expression of MEG3 in chondrocytes transfected by LV‐MEG3 or negative control, followed by treatment of LPS. E, Proliferative activity of chondrocytes in CCK‐8 assay. F, Crystal violet staining results of chondrocytes. G, Protein expressions of Ki67 and PCNA by Western blotting assay. H, Protein expressions of IL‐17 and IL‐23 by Western blotting assay. \**P* \< .05; \*\**P* \< .01](JCMM-23-7116-g001){#jcmm14591-fig-0001}

To investigate how MEG3 affects LPS‐treated changes in chondrocytes, we determined the changes in MEG3 level upon LPS treatment. Results showed MEG3 expression was markedly decreased in LPS‐treated chondrocytes (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}A). To find out how MEG3 affects the LPS‐treated changes in proliferation and inflammation of chondrocytes, we overexpressed MEG3 using lentivirus vectors (Figure [1](#jcmm14591-fig-0001){ref-type="fig"}D**)**.As shown in Figure [1](#jcmm14591-fig-0001){ref-type="fig"}E and [1](#jcmm14591-fig-0001){ref-type="fig"}, in comparison with the LPS or Lentiviral (LV) groups, cell viability and proliferation were significantly enhanced in case of MEG3 overexpression. We also found that overexpressed MEG3 up‐regulated Ki67 and PCNA in LPS‐treated chondrocytes (Figure [1](#jcmm14591-fig-0001){ref-type="fig"}G). Moreover, IL‐23 and IL‐17, the pro‐inflammatory cytokines, were down‐regulated upon MEG3 overexpression (Figure [1](#jcmm14591-fig-0001){ref-type="fig"}H). These results indicate that MEG3 protects chondrocytes in the presence of LPS through relieving the inhibitory effect on proliferation as well as down‐regulating the release of pro‐inflammatory cytokines.

![Overexpressing miR‐141 abolished the protective effect of MEG3 on LPS‐treated chondrocytes. A, MEG3 sequences targeted by has‐miR‐141 were analysed by bioinformatics. B, mRNA expression of miR‐141 by RT‐PCR. C, Cell viability assessment using CCK‐8 kit. D, Expressions of Ki67 and PCNA determined by Western blotting assay. E, Protein expressions of IL‐17 and IL‐23 by Western blotting assay. F, Protein expressions of p‐ERK1/2, p‐p65 and p‐P38 were determined by Western blotting. G, Protein expressions of p‐AKT, p‐mTOR and p‐S6K were determined by Western blotting. H, mRNA expression of MEG3 by RT‐PCR. I, mRNA expression of miR‐141 by RT‐PCR. J, Distribution and expressions of Ki67 and PCNA by immunohistochemistry. K, Quantity of CD4^+^ IL‐17^+^ and CD4^+^ IL‐23^+^ cells by FCM. L, Protein expressions of p‐AKT, p‐mTOR and p‐S6K by Western blotting assay. \*\**P* \< .01](JCMM-23-7116-g002){#jcmm14591-fig-0002}

3.2. Effect of MEG3 on LPS‐treated chondrocytes was reversed by miR‐141 overexpression {#jcmm14591-sec-0015}
--------------------------------------------------------------------------------------

It was predicted that there was a possible site on MEG3 sequences that could bind to miR‐141 (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}A), suggesting that they could be correlated. As shown in Figure [2](#jcmm14591-fig-0002){ref-type="fig"}B, miR‐141 was up‐regulated evidently in presence of LPS, in comparison with the control group.

In order to elucidate the role of miR‐141 in the effect exerted by MEG3 on LPS‐treated chondrocytes, a series of transfections were performed using LV‐MEG3, miR‐141 mimic, or the combination, and then treated with LPS. LV‐MEG3 overexpression might protect the cells from LPS‐treated inhibition of proliferation and inflammatory factors production, which was reversed after transfection with miR‐141 mimics (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}C‐E). Thus, under conditions of miR‐141 overexpression, the protective role of MEG3 might be abolished, in part, in LPS‐treated chondrocyte.

3.3. MEG3 deactivated miR‐141‐mediated AKT/mTOR signal pathway in LPS‐treated chondrocytes {#jcmm14591-sec-0016}
------------------------------------------------------------------------------------------

As shown in Figure [2](#jcmm14591-fig-0002){ref-type="fig"}F and [2](#jcmm14591-fig-0002){ref-type="fig"}, level of p‐ERK1/2, p‐AKT, p‐P38 and p65 were increased in the presence of LPS. In case of MEG3 and miR‐141 overexpression, we found no changes in level of p‐ERK1/2, p‐p65 and p‐P38. However, p‐AKT, p‐mTOR and p‐S6 level were significantly down‐regulated in the LV‐MEG3 group, in comparison with the LPS group, and this down‐regulation was abolished after transfection using miR‐141 mimics. Thus, MEG3/miR‐141 primarily functions by the AKT/mTOR pathway in LPS‐treated signalling.

3.4. MEG3 enhanced cell proliferation and suppressed inflammation in vivo {#jcmm14591-sec-0017}
-------------------------------------------------------------------------

To further clarify the function of MEG3, we carried out in vivo experiments in RA model of rats that were established by infusing LV‐MEG3 subcutaneously. In Figure [2](#jcmm14591-fig-0002){ref-type="fig"}H and [2](#jcmm14591-fig-0002){ref-type="fig"}, MEG3 was up‐regulated after LV‐MEG3 treatment, with a decrease in miR‐141 expression. Ki67 and PCNA levels were augmented in tissue samples with MEG3 overexpression (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}J**)**. Results of Flow cytometry (FCM) revealed that CD4^+^ IL‐23^+^ cells were significantly reduced under the conditions of MEG3 overexpression (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}K). Moreover, MEG3 overexpression down‐regulated the level of p‐AKT in vivo (Figure [2](#jcmm14591-fig-0002){ref-type="fig"}L). Thus, we inferred that MEG3 down‐regulates miR‐141, promotes cell proliferation, reduces Th17 cells and inactivates AKT/mTOR signal pathway in vivo.

4. DISCUSSION {#jcmm14591-sec-0018}
=============

With the rapid progress in transcriptome sequencing, different lncRNAs are being identified to be related to different diseases, including RA.[23](#jcmm14591-bib-0023){ref-type="ref"}, [24](#jcmm14591-bib-0024){ref-type="ref"} Previous study indicated the potential role of MEG3 in RA.[25](#jcmm14591-bib-0025){ref-type="ref"} Also, it is important to understand the effect of MEG3 in RA as well as the underlying molecular mechanism. In this study, we found that the suppressed proliferation of chondrocytes that was induced by LPS was reversed by MEG3 overexpression. Furthermore, we found that Ki67 and PCAN were up‐regulated under the conditions of MEG3 overexpression in LPS‐treated chondrocytes. Besides, we also identified a close correlation between inflammatory cytokines and RA. In comparison with the LPS group, overexpressed MEG3 reduced IL‐23 expression remarkably, demonstrating the vital role of MEG3 in the proliferation and inflammatory responses of LPS‐treated chondrocytes.

In this study, we aimed to validate a hypothesis: there is a target relationship between MEG3 and miR‐141, which can be illustrated by bioinformatics‐based prediction. In the presence of LPS, we found that miR‐141 was up‐regulated significantly, in comparison with the control group, which, however, was reversed after MEG3 was overexpressed. Transfection with a miR‐141 mimic significantly reduced cell proliferation and increased the level of IL‐23, prompting that LPS‐induced injuries to chondrocyte may be aggravated in case of miR‐141 overexpression. After chondrocytes were transfected using miR‐141 mimics, the protective effect of MEG3 was abolished on LPS‐treated chondrocytes. Thus, MEG3 can protect the chondrocytes from the LPS‐induced injuries, which is partially due to the inhibition of miR‐141. To discover the role of AKT/mTOR signal pathway in modulating the levels of MEG3 and miR‐141 in LPS‐treated chondrocyte, we studied AKT, p‐AKT, mTOR and p‐mTOR, and found that the AKT/mTOR pathway was activated. In RA models, overexpressed MEG3 increased the expression of Ki67 and PCNA and reduced the number of CD4^+^ IL‐23^+^ cells with down‐regulation in inflammatory cytokines, which were in agreement with the results of in vitro experiments. Thus, MEG3 promotes in vitro and in vivo proliferation of cells and suppresses inflammation.
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